In 2025, Brazilian medication distributors, including Viveo, Profarma, 4Bio, and Concordo, generated a total revenue of R$ 42 billion. This figure represents an 11.6% growth compared to 2024 and a remarkable 35% increase over the preceding two years. The firms are affiliated with Abradimex, which specializes in the distribution of specialized, exceptional, and hospital medications. The rise in revenue can be attributed to both market expansion and an aging population requiring more complex medical treatments, accentuated by improved logistics and support services offered by distributors.

The distribution of 91 million medications and medical supplies to over 18,000 public and private hospitals, clinics, and specialty pharmacies underscores the critical role these distributors play in the healthcare system. With 80% of their sales driven by the private sector, these companies respond to the growing demand for health services as they adapt their offerings to better serve patients. This expansion is significant as it highlights the healthcare industry's ongoing transformation, particularly in how medications are delivered and managed within Brazil.

Paulo Maia, the executive president of Abradimex, pointed to demographic changes, particularly the aging population, as a key factor driving this demand for advanced treatments. Additionally, pharmaceutical laboratories are focusing their efforts on research and development, thereby delegating logistical functions to distributors, which further enhances the overall efficiency and effectiveness of the medication supply chain in Brazil. This trend signals a shift in how the pharmaceutical industry is structuring its operational framework to meet future healthcare needs more effectively.